24 terminated. 24 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 24 | Terminated 24 |
| Phase 2 | 3 | Terminated 3 |
Follow Thromboembolism: new trials by email Literature Review of Thromboembolism trials Research Report on Thromboembolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Abelacimab, Dalteparin - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 417 | 2022-09-27 | 2026-04-17 |
| THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) Rivaroxaban 10 MG, Placebo - Sickle Cell Disease, Central Venous Catheter Thrombosis | Phase 3 | Terminated | University Health Network, Toronto | 4 | 2022-06-07 | 2025-03-19 |
| A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Abelacimab, Apixaban - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 1150 | 2022-05-05 | 2026-02-23 |
| Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE) Tinzaparin Sodium - Venous Thromboembolism, Lung Neoplasm | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 59 | 2018-09-14 | 2022-11-17 |
| Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants Apixaban, Rivaroxaban, Heparin - Renal Insufficiency | Phase 3 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 203 | 2016-10-19 | 2022-10-19 |
| Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients Rivaroxaban, low-molecular heparine - Venous Thromboembolism, Cancer | Phase 3 | Terminated | AIO-Studien-gGmbH | 246 | 2016-03-23 | 2021-05-03 |
| Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome. Enoxaparin - Nephrotic Syndrome | Phase 2 / Phase 3 | Terminated | Military Institute od Medicine National Research Institute | 65 | 2015-10-01 | 2023-01-30 |
| Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo - Stroke | Phase 3 | Terminated | Bayer | 7213 | 2014-12-23 | 2019-01-09 |
| Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia Rivaroxaban - Heparin-induced Thrombocytopenia | Phase 3 | Terminated | McMaster University | 22 | 2013-01-01 | 2016-03-25 |
| PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients Enoxaparin, Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization - Hemorrhagic Stroke, Venous Thromboembolism | Phase 3 | Terminated | University Of Perugia | 73 | 2012-05-01 | 2021-09-10 |
| Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis Endovascular thrombolysis, Heparin - Sinus Thrombosis, Intracranial | Phase 2 / Phase 3 | Terminated | Jan Stam, MD, PhD | 67 | 2011-09-01 | 2017-02-14 |
| Statin in Hip Fracture Rosuvastatin, Placebo - Hip Fracture | Phase 3 | Terminated | University Hospital, Brest | 36 | 2011-08-01 | 2012-09-20 |
| Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism low molecular weight heparin, vitamin K antagonists - Venous Thromboembolism, Neoplasms | Phase 3 | Terminated | University Medical Center Groningen | 56 | 2010-08-01 | 2014-12-03 |
| A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients dalteparin injection - Venous Thromboembolism, Pulmonary Embolism | Phase 3 | Terminated | University of Rochester | 218 | 2009-07-01 | 2015-11-24 |
| Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility Semuloparin sodium, Enoxaparin sodium - Venous Thromboembolism | Phase 3 | Terminated | Sanofi | 421 | 2008-07-01 | 2013-01-23 |
| Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation Tapered warfarin regimen, Bridged regimen Low-molecular-weight heparin - Cardiac Arrhythmias, Hemorrhage | Phase 3 | Terminated | McMaster University | 173 | 2007-12-01 | 2016-04-05 |
| Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer daltéparine, Chemotherapy at the investigator's discretion - Chemotherapeutic Agent Toxicity, Pancreatic Cancer | Phase 3 | Terminated | GERCOR - Multidisciplinary Oncology Cooperative Group | 42 | 2007-10-01 | 2013-03-13 |
| Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients Fondaparinux, Enoxaparin - Venous Thromboembolism | Phase 3 | Terminated | Eastern Virginia Medical School | 27 | 2007-07-01 | 2022-04-11 |
| Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism Arixtra alone, Arixtra + filter - Cancer, Thromboembolism | Phase 3 | Terminated | Northwell Health | 64 | 2007-01-01 | 2016-06-08 |
| Evaluation of the TriActiv ProGuard System During Carotid Artery Stenting Carotid Stent Implantation, Embolic Protection - Carotid Stenosis | Phase 2 / Phase 3 | Terminated | Kensey Nash Corporation | 400 | 2006-11-01 | 2007-07-25 |
Showing 20 of 24. Sign in to see all of them.
Venous Thromboembolism (16) · Venous Thrombosis (7) · Pulmonary Embolism (5) · Neoplasms (3) · Pancreatic Neoplasms (2) · Stroke (2) · Anemia, Sickle Cell (1) · Arrhythmias, Cardiac (1) · Arterial Occlusive Diseases (1) · Atrial Fibrillation (1) · Carotid Stenosis (1) · Cerebrovascular Disorders (1) · Embolism (1) · Gastrointestinal Neoplasms (1)
Cardiovascular Diseases (24) · Embolism and Thrombosis (24) · Vascular Diseases (24) · Thrombosis (8) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Brain Diseases (5) · Central Nervous System Diseases (5) · Embolism (5) · Nervous System Diseases (5) · Cerebrovascular Disorders (4) · Neoplasms (4) · Neoplasms by Site (4) · Digestive System Diseases (3)
Enoxaparin (5) · Rivaroxaban (5) · Dalteparin (4) · Fondaparinux (2) · Heparin (2) · Heparin, Low-Molecular-Weight (2) · MAA868 (2) · Tinzaparin (2) · abelacimab (2) · acarboxyprothrombin (2) · apixaban (2) · AVE 5026 (1) · Acenocoumarol (1) · Aspirin (1) · Embolic Protection Devices (1)
Anthos Therapeutics, Inc. (2) · McMaster University (2) · AIO-Studien-gGmbH (1) · ARCA Biopharma, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Bayer (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Eastern Virginia Medical School (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · Gary Morrow (1) · Hamilton Health Sciences Corporation (1) · Jan Stam, MD, PhD (1) · Kensey Nash Corporation (1) · Military Institute od Medicine National Research Institute (1)
Canada (11) · France (10) · United States (10) · Germany (8) · Italy (7) · Netherlands (6) · Austria (5) · Hungary (5) · Spain (5) · Switzerland (5) · Australia (4) · China (4) · Czechia (4) · South Korea (4) · Sweden (4)
Alexander Turpie, MD (1) · Anna Matyjek, MD, PhD (1) · Benoist Chibauldel, MD (1) · Charles BL Majoie, MD, PhD (1) · Charles W Callender, MD (1) · Charles W. Francis, MD (1) · Daniel R. Budman, MD (1) · E Houdart, MD, PhD (1) · Gary S Roubin, MD (1) · Guy Meyer, MD (1) · Harry R. Buller, MD, PhD (1) · Isabelle Crassard, MD, PhD (1)
PMID 33337539, PMID 18485453, PMID 22340437, PMID 25127655, PMID 28139259, PMID 29525076, PMID 29766772, PMID 31008276, PMID 31401971, PMID 31526123, PMID 32056346, PMID 32295509, PMID 32421159, PMID 32517582, PMID 32628266, PMID 32640945, PMID 33074284, PMID 33190135, PMID 34172290, PMID 34538089, PMID 34694346, PMID 34791941, PMID 34884411, PMID 35470214, PMID 36700520, PMID 38171625, PMID 39358761, PMID 41249873
2016 (2), 2008 (1), 2023 (1), R01HL095109 (1)